AHRQ (Agency for Healthcare Research and Quality) casts doubt on TMR/PMR (transmyocardial revascularisation)/(percutaneous myocardial revascularisation) for angina
This article was originally published in Clinica
Executive Summary
A new Medicare-commissioned technology assessment is highly critical of transmyocardial revascularisation (TMR) and percutaneous myocardial revascularisation (PMR) as a way of treating the crushing pain of angina. The report by the federal Agency for Healthcare Research and Quality (AHRQ) was released ahead of an upcoming Medicare Coverage Advisory Committee meeting on TMR and PMR and could induce Medicare to curtail its coverage of the two technologies.
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.